Press Releases
2024
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2023
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2022
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2021
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2020
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2019
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2018 & Prior
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Media
The Case for RRx-001 as a Radiation Countermeasure
A pandemic waiting to happen: Acute radiation syndrome and the immediate need for nuclear countermeasures
Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug
PREVLAR: Phase 2a randomized trial to assess the safety and efficacy of RRx-001 in the attenuation of oral mucositis in patients receiving head and neck chemoradiotherapy
RRx-001 Plus Irinotecan Improves Efficacy vs Regorafenib in Colorectal Cancer
FightMND Supports ALS Research on Inflammasome Blocker RRx-001
EBOOK Drug Target Review Immuno-oncology ebook 2022
ARMED ONCOLYTIC VIRUSES – Instant Messaging Cancer With a TGF-Beta Trap Carrying Oncolytic Adenovirus
What Exactly Is Inflammation (and What Is It Not?)
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot
Dr. Tony Reid, MD, PhD interview with Oncology Tube – REPLATINUM Phase III
The Dictatorship of Cancer: How to Topple it in Three – Not So Easy – Steps
What do dictators and the military have in common with tumors and stroma? The answer: symbiosis – a relationship in which two different types closely and intimately interact with each other to the benefit of at least one of the types. The famous phrase, “no man is an...
A next-gen vaccine that could help end COVID-19 whack-a-mole
EpicentRx used its AdAPT Platform to develop a nucleocapsid-based next-gen COVID 19 vaccine candidate and is ready for clinical trials. CEO Dr. Tony Reid recently discussed with Drug Discovery & Development.
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
Next-generation SARS-CoV-2 nucleocapsid-based vaccines may provide optimal protection against infection
Neuroendocrine Tumors Market to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – EpicentRx, Pfizer, Ignyta, Amgen, Progenics Pharma, Hutchison MediPharma, and Others
Clinical Catch-Up: COVID-19 Updates from Sinovac, Moderna, Arcturus, Novavax and More
EpicentRx begins Phase I trial of paediatric CNS tumour treatment
Several Players Begin 2022 with New Partnerships in Place
BioSpace
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
BioSpace
AdAPT-001 Mechanism of Action
AdAPT-001 doesn’t just create a cancer-targeted infection, it produces a proprietary TGFβ “trap”...
Conferences
American Society of Hematology (ASH) 2012
December 2012, Atlanta Georgia
Abstract: Treatment with a novel dinitroazetidine, ABDNAZ, improves nitrite reductase activity of sickle red blood cells
American Association for Cancer Research (AACR) Annual Meeting 2012
March 2012, Chicago Illinois
Abstract: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors
American Society of Hematology (ASH) 2011
December 2011, San Diego, California
Abstract: NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells
International Society for the Study of Xenobiotics (ISSX) 2011
April 2011, Atlanta, Georgia
Abstract: Disposition of 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys, and humans
American Association for Cancer Research (AACR) Annual Meeting 2011
April 2011, Orlando, Florida
Abstract: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials’